Collaboration to advance AAV production enhancers
A Canadian Japanese co-innovation programme is set to advance AAV production enhancers.
AAV vectors are a cornerstone of in vivo gene delivery for gene therapies, but they remain difficult and expensive to manufacture at scale. As pipelines expand to more indications and broader patient populations, significantly greater amounts of high-quality AAV are required, while the need for commercially viable therapies places pressure on cost-of-goods.
A co-innovation programme between cell enhancer company Virica Biosciences and FUJIFILM Biosciences is now set to optimise a VSE formulation for FUJIFILM’s HEK293 media to support academic and commercial AAV producers globally.
As part of the collaboration, the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) has provided Virica with advisory services and funding.
“We see a strong fit between our VSE technology and FUJIFILM Biosciences BalanCD media portfolio,” said Dr Jean-Simon Diallo, Scientific Co-Founder and Chief Executive Officer of Virica Biotech.
“Following the recent launch of our CellVantage-AAV off-the-shelf enhancer, our goal is to provide an optimised formulation to deliver further AAV productivity gains specifically in the FUJIFILM Biosciences BalanCD HEK293 system.”
“We remain committed to offering integrated solutions that combine high-performance media with enabling technologies,” added Yutaka Yamaguchi, Chairman and Chief Executive Officer at FUJIFILM Biosciences.
“Optimising Virica’s VSE-based enhancers with our FUJIFILM Biosciences BalanCD HEK293 system will help us deliver an easy-to-implement option for improving AAV yields and supporting efficient scale-up for our customers.”
